Patent intelligence · US
US 12274696
Methods of administering nalbuphine
Methods of administering nalbuphine
Patent details — US 12274696
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 15, 2025
- Expiration
- Apr 10, 2045
- Applicant
- Trevi Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/485, A61K9/205, A61P
Quick answer
US 12274696 (Methods of administering nalbuphine) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Trevi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/485, A61K9/205, A61P, A61P11/00, A61P17/04
More from Trevi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11660296
Treatment of chronic cough, breathlessness and dyspnea
granted -
US 10238646
Methods for treating pruritus
granted -
US 9624233
Compounds for treating pruritic conditions
granted -
US 8987289
Methods for treating pruritus
granted -
US 8940753
Methods for treating pruritis
granted -
US 8637538
Methods for treatment of pruritis
granted
Frequently asked questions
What is US patent 12274696?
US 12274696 (Methods of administering nalbuphine) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12274696?
Trevi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12274696 expire?
Our index shows an expiration date of Apr 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.